Ms. Philippa Lewis reports

ASX APPENDIX 4C FOR THE QUARTER ENDED DECEMBER 31, 2014

Simavita Ltd. has released its Australian Securities Exchange Appendix 4C for the quarter ended Dec. 31, 2014.

Cash receipts from customers for the quarter were $130,326, taking the total for the first six months of the 2015 financial year to $220,549. However, as the Appendix 4C is a cash flow report, this figure does not include revenue from United States distributor Medline's first major order, which was recorded as a debtor as at Dec. 31, 2014.

As reported on Jan. 6, 2015, the company's preliminary (unaudited) sales revenue for the first half of the 2015 financial year was $458,082. This figure, which represents a record result for the company, compares favourably with the total sales revenue for the entire 2014 financial year of $349,895. When compared with the total sales revenue for the corresponding half year in 2014 of $151,283, the current period results represent an increase of more than 200 per cent.

Simavita's consolidated cash and cash equivalents decreased during the half year ended Dec. 31, 2014, by $1,917,070, such that the cash balance as at that date was $4,927,127. The company anticipates that it will receive a payment under the Australian government's research and development tax incentive scheme in the order of $1.2-million in the near future.

We seek Safe Harbor.